Overview

Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose solution for inhalation in patients with chronic obstructive airways disease in daily practice
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Fenoterol
Fenoterol, ipratropium drug combination
Ipratropium
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- Men and women presenting with symptoms of chronic obstructive pulmonary disease

- Both previously untreated patients and patients treated previously with Berodual® or
with other anti-obstructive respiratory tract agents may be included

Exclusion Criteria:

- Patients presenting with the general and specific contraindications listed in the
Patient Information Leaflet and the Basic Product Information